San Francisco, California, July 17, 2017: A recent market research report by TMR Research covers the global market for cardiogenic shock. The report, titled “Cardiogenic Shock Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” presents thorough insights into the present growth prospects of the market and includes several projections regarding the growth prospects of the market over the period between 2017 and 2025.
The report states that the market will exhibit a steady rise in demand across the globe over the said period, with a number of factors contributing to the rise in need for cardiogenic shock treatments. Factors such as the rising inclusion of junk food in everyday diets, sedentary lifestyles, and a vast reduction in physical activities are key causative agents of a number of cardiac conditions. As the prevalence of cardiac conditions increases on a global front, the pressing need for effective treatments is being felt, also driving research and development activities in the field of cardiogenic shock treatments.
The market for cardiogenic shock is also expected to benefit from the rising focus of government and private bodies on improvement of healthcare facilities and providing economical and effective treatments to the population. Rise in funds are ensuring the availability of cardiac shock equipment across healthcare facilities across distant corners of the globe. The rising level of awareness among consumers about available treatment modalities to treat cardiogenic shock is also proving beneficial for the global cardiogenic shock market.
From a geographical standpoint, the market for cardiogenic shock in North America led the global market in terms of revenue contribution in 2016. The regional market also held a commanding position in the market in terms of rate of procedural and technological advancements. The region features a high level of awareness regarding healthcare and has an encouraging reimbursement scenario, boosting the adoption of advanced healthcare equipment and treatment methods.
Europe held the second-leading position in the global cardiogenic shock market in 2016, chiefly owing to the presence of numerous medical device and pharmaceutical companies, well-established healthcare infrastructure, and rising prevalence of the condition. The region will continue to remain one of the key regional markets for cardiogenic shock treatment in the next few years as well. However, regions such as Asia Pacific and Latin America are projected to present promising growth opportunities for the cardiogenic shock market owing to vast set of unmet needs, rising populations, and increasing expenditure on healthcare.
Some of the leading companies operating in the global cardiogenic shock market are Clinical Research Foundation Inc., NeuroVive Pharmaceutical AB, ArgiNOx Pharmaceuticals, Inc., BTG Plc., Eli Lilly and Company, and Abbott Laboratories.